1921
Volume 90, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Protective immunity to cholera is serogroup specific, and serogrouping is defined by the O-specific polysaccharide (OSP) of lipopolysaccharide (LPS). We characterized OSP-specific immune responses in adult recipients of an oral killed cholera vaccine (OCV WC-rBS) and compared these with responses in patients with cholera caused by O1 Ogawa. Although vaccinees developed plasma immunoglobulin G (IgG), IgM, IgA antibody and antibody secreting cell (ASC, marker of mucosal response) to Ogawa OSP and LPS 7 days after vaccination, responses were significantly lower than that which occurred after cholera. Similarly, patients recovering from cholera had detectable IgA, IgM, and IgG memory B cell (MBC) responses against OSP and LPS on Day 30 and Day 90, whereas vaccinees only developed IgG responses to OSP 30 days after the second immunization. The markedly lower ASC and MBC responses to OSP and LPS observed among vaccinees might explain, in part, the lower protection of an OCV compared with natural infection.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.13-0498
2014-05-07
2017-11-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/90/5/873.html?itemId=/content/journals/10.4269/ajtmh.13-0498&mimeType=html&fmt=ahah

References

  1. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB, , 2012. Cholera. Lancet 379: 24662476.[Crossref]
  2. Zuckerman JN, Rombo L, Fisch A, , 2007. The true burden and risk of cholera: implications for prevention and control. Lancet Infect Dis 7: 521530.[Crossref]
  3. Anonymous, 2010. Cholera vaccines: WHO position paper-recommendations. Vaccine 28: 46874688.[Crossref]
  4. Stroeher UH, Karageorgos LE, Morona R, Manning PA, , 1992. Serotype conversion in Vibrio cholerae O1. Proc Natl Acad Sci USA 89: 25662570.[Crossref]
  5. Hisatsune K, Kondo S, Isshiki Y, Iguchi T, Haishima Y, , 1993. Occurrence of 2-O-methyl-N-(3-deoxy-L-glycero-tetronyl)-D-perosamine (4-amino-4,6-dideoxy-D-manno-pyranose) in lipopolysaccharide from Ogawa but not from Inaba O forms of O1 Vibrio cholerae . Biochem Biophys Res Commun 190: 302307.[Crossref]
  6. Wang J, Villeneuve S, Zhang J, Lei P, Miller CE, Lafaye P, Nato F, Szu SC, Karpas A, Bystricky S, Robbins JB, Kovac P, Fournier JM, Glaudemans CP, , 1998. On the antigenic determinants of the lipopolysaccharides of Vibrio cholerae O:1, serotypes Ogawa and Inaba. J Biol Chem 273: 27772783.[Crossref]
  7. Ito T, Higuchi T, Hirobe M, Hiramatsu K, Yokota T, , 1994. Identification of a novel sugar, 4-amino-4,6-dideoxy-2-O-methylmannose in the lipopolysaccharide of Vibrio cholerae O1 serotype Ogawa. Carbohydr Res 256: 113128.[Crossref]
  8. Harris AM, Chowdhury F, Begum YA, Khan AI, Faruque AS, Svennerholm AM, Harris JB, Ryan ET, Cravioto A, Calderwood SB, Qadri F, , 2008. Shifting prevalence of major diarrheal pathogens in patients seeking hospital care during floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. Am J Trop Med Hyg 79: 708714.
  9. Anh DD, Canh do G, Lopez AL, Thiem VD, Long PT, Son NH, Deen J, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Holmgren J, Clemens J, , 2007. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25: 11491155.[Crossref]
  10. Mahalanabis D, Lopez AL, Sur D, Deen J, Manna B, Kanungo S, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Rao R, Holmgren J, Clemens J, Bhattacharya SK, , 2008. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS ONE 3: e2323.[Crossref]
  11. Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, Qadri F, , 2011. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29: 82858292.[Crossref]
  12. Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Donner A, Ganguly NK, Nair GB, Bhattacharya SK, Clemens JD, , 2009. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomized, double-blind, placebo-controlled trial. Lancet 374: 16941702.[Crossref]
  13. Kanungo S, Paisley A, Lopez AL, Bhattacharya M, Manna B, Kim DR, Han SH, Attridge S, Carbis R, Rao R, Holmgren J, Clemens JD, Sur D, , 2009. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 27: 68876893.[Crossref]
  14. Clemens JD, van Loon F, Sack DA, Rao MR, Ahmed F, Chakrabort YJ, Kay BA, Khan MR, Yunus MD, Harris JR, Clemens JD, Rao MR, Svennerholm A-M, Holmgren J, , 1991. Biotype as determinant of natural immunizing effect of cholera. Lancet 337: 883884.[Crossref]
  15. Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Han SH, Attridge S, Donner A, Ganguly NK, Bhattacharya SK, Nair GB, Clemens JD, Lopez AL, , 2011. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis 5: e1289.[Crossref]
  16. Ali M, Emch M, Park JK, Yunus M, Clemens J, , 2011. Natural cholera infection-derived immunity in an endemic setting. J Infect Dis 204: 912918.[Crossref]
  17. Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR, , 1981. Duration of infection-derived immunity to cholera. J Infect Dis 143: 818820.[Crossref]
  18. Albert MJ, Alam K, Rahman AS, Huda S, Sack RB, , 1994. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J Infect Dis 169: 709710.[Crossref]
  19. Waldor MK, Colwell R, Mekalanos JJ, , 1994. The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants. Proc Natl Acad Sci USA 91: 1138811392.[Crossref]
  20. Qadri F, Wenneras C, Albert MJ, Hossain J, Mannoor K, Begum YA, Mohi G, Salam MA, Sack RB, Svennerholm AM, , 1997. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect Immun 65: 35713576.
  21. Xu P, Alam MM, Kalsy A, Charles RC, Calderwood SB, Qadri F, Ryan ET, Kovac P, , 2011. Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines. Bioconjug Chem 22: 21792185.[Crossref]
  22. Cox AD, Brisson JR, Varma V, Perry MB, , 1996. Structural analysis of the lipopolysaccharide from Vibrio cholerae O139. Carbohydr Res 290: 4358.[Crossref]
  23. Cox AD, Perry MB, , 1996. Structural analysis of the O-antigen-core region of the lipopolysaccharide from Vibrio cholerae O139. Carbohydr Res 290: 5965.[Crossref]
  24. Vinogradov EV, Bock K, Holst O, Brade H, , 1995. The structure of the lipid A-core region of the lipopolysaccharides from Vibrio cholerae O1 smooth strain 569B (Inaba) and rough mutant strain 95R (Ogawa). Eur J Biochem 233: 152158.[Crossref]
  25. Hankins JV, Madsen JA, Giles DK, Brodbelt JS, Trent MS, , 2012. Amino acid addition to Vibrio cholerae LPS establishes a link between surface remodeling in Gram-positive and Gram-negative bacteria. Proc Natl Acad Sci USA 109: 87228727.[Crossref]
  26. Johnson RA, Uddin T, Aktar A, Mohasin M, Alam MM, Chowdhury F, Harris JB, LaRocque RC, Bufano MK, Yu Y, Wu-Freeman Y, Leung DT, Sarracino D, Krastins B, Charles RC, Xu P, Kovac P, Calderwood SB, Qadri F, Ryan ET, , 2012. Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera. Clin Vaccine Immunol 19: 17121721.[Crossref]
  27. Leung DT, Uddin T, Xu P, Aktar A, Johnson RA, Rahman MA, Alam MM, Bufano MK, Eckhoff G, Wu-Freeman Y, Yu Y, Sultana T, Khanam F, Saha A, Chowdhury F, Khan AI, Charles RC, Larocque RC, Harris JB, Calderwood SB, Kovac P, Qadri F, Ryan ET, , 2013. Immune responses to the O-specific polysaccharide antigen in children receiving a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin Vaccine Immunol 20: 780.[Crossref]
  28. Alam MM, Riyadh MA, Fatema K, Rahman MA, Akhtar N, Ahmed T, Chowdhury MI, Chowdhury F, Calderwood SB, Harris JB, Ryan ET, Qadri F, , 2011. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin Vaccine Immunol 18: 844850.[Crossref]
  29. Qadri F, Asaduzzaman M, Wenneras C, Mohi G, Albert MJ, Abdus Salam M, Sack RB, Jertborn M, McGhee JR, Sack DA, Holmgren J, , 2000. Enterotoxin-specific immunoglobulin E responses in humans after infection or vaccination with diarrhea-causing enteropathogens. Infect Immun 68: 60776081.[Crossref]
  30. Qadri F, Raqib R, Ahmed F, Rahman T, Wenneras C, Das SK, Alam NH, Mathan MM, Svennerholm AM, , 2002. Increased levels of inflammatory mediators in children and adults infected with Vibrio cholerae O1 and O139. Clin Diagn Lab Immunol 9: 221229.
  31. Jayasekera CR, Harris JB, Bhuiyan S, Chowdhury F, Khan AI, Faruque AS, Larocque RC, Ryan ET, Ahmed R, Qadri F, Calderwood SB, , 2008. Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1. J Infect Dis 198: 10551061.[Crossref]
  32. Harris AM, Bhuiyan MS, Chowdhury F, Khan AI, Hossain A, Kendall EA, Rahman A, LaRocque RC, Wrammert J, Ryan ET, Qadri F, Calderwood SB, Harris JB, , 2009. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 77: 38503856.[Crossref]
  33. Kendall EA, Tarique AA, Hossain A, Alam MM, Arifuzzaman M, Akhtar N, Chowdhury F, Khan AI, Larocque RC, Harris JB, Ryan ET, Qadri F, Calderwood SB, , 2009. Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-dependent antigen following infection with Vibrio cholerae O1 in Bangladesh. Infect Immun 78: 253259.[Crossref]
  34. Qadri F, Mohi G, Hossain J, Azim T, Khan AM, Salam MA, Sack RB, Albert MJ, Svennerholm AM, , 1995. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin Diagn Lab Immunol 2: 685688.
  35. Qadri F, Ryan ET, Faruque AS, Ahmed F, Khan AI, Islam MM, Akramuzzaman SM, Sack DA, Calderwood SB, , 2003. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun 71: 48084814.[Crossref]
  36. Shamsuzzaman S, Ahmed T, Mannoor K, Begum YA, Bardhan PK, Sack RB, Sack DA, Svennerholm AM, Holmgren J, Qadri F, , 2009. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses. Vaccine 27: 13861392.[Crossref]
  37. Uddin T, Harris JB, Bhuiyan TR, Shirin T, Uddin MI, Khan AI, Chowdhury F, LaRocque RC, Alam NH, Ryan ET, Calderwood SB, Qadri F, , 2011. Mucosal immunologic responses in cholera patients in Bangladesh. Clin Vaccine Immunol 18: 506512.[Crossref]
  38. Crotty S, Aubert RD, Glidewell J, Ahmed R, , 2004. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 286: 111122.[Crossref]
  39. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R, , 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171: 49694973.[Crossref]
  40. Qadri F, Jonson G, Begum YA, Wenneras C, Albert MJ, Salam MA, Svennerholm AM, , 1997. Immune response to the mannose-sensitive hemagglutinin in patients with cholera due to Vibrio cholerae O1 and O0139. Clin Diagn Lab Immunol 4: 429434.
  41. Czerkinsky C, Prince SJ, Michalek SM, Jackson S, Russell MW, Moldoveanu Z, McGhee JR, Mestecky J, , 1987. IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc Natl Acad Sci USA 84: 24492453.[Crossref]
  42. Koelle K, Rodo X, Pascual M, Yunus M, Mostafa G, , 2005. Refractory periods and climate forcing in cholera dynamics. Nature 436: 696700.[Crossref]
  43. Patel SM, Rahman MA, Mohasin M, Riyadh MA, Leung DT, Alam MM, Chowdhury F, Khan AI, Weil AA, Aktar A, Nazim M, LaRocque RC, Ryan ET, Calderwood SB, Qadri F, Harris JB, , 2012. Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh. Clin Vaccine Immunol 19: 842848.[Crossref]
  44. Leung DT, Rahman MA, Mohasin M, Patel SM, Aktar A, Khanam F, Uddin T, Riyadh MA, Saha A, Alam MM, Chowdhury F, Khan AI, Charles R, LaRocque R, Harris JB, Calderwood SB, Qadri F, Ryan ET, , 2012. Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin Vaccine Immunol 19: 690698.[Crossref]
  45. Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI, Holmgren J, , 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151: 236242.[Crossref]
  46. Saha D, LaRocque RC, Khan AI, Harris JB, Begum YA, Akramuzzaman SM, Faruque AS, Ryan ET, Qadri F, Calderwood SB, , 2004. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J Infect Dis 189: 23182322.[Crossref]
  47. Losonsky GA, Yunyongying J, Lim V, Reymann M, Lim YL, Wasserman SS, Levine MM, , 1996. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect Immun 64: 1015.
  48. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque AS, Ryan ET, Qadri F, Calderwood SB, , 2008. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis 2: e221.[Crossref]
  49. Leung DT, Rahman MA, Mohasin M, Riyadh MA, Patel SM, Alam MM, Chowdhury F, Khan AI, Kalivoda EJ, Aktar A, Bhuiyan MS, LaRocque RC, Harris JB, Calderwood SB, Qadri F, Ryan ET, , 2011. Comparison of memory B cell, antibody-secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh. Clin Vaccine Immunol 18: 13171325.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.13-0498
Loading
/content/journals/10.4269/ajtmh.13-0498
Loading

Data & Media loading...

  • Received : 28 Aug 2013
  • Accepted : 24 Dec 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error